TL;DR: The AdvisorShares Pure US Cannabis ETF (MSOS) advanced 2.48% in the holiday-shortened trading week ending July 3, 2026, as the benchmark cannabis sector fund entered Sunday’s market break with net assets of $1.02 billion and a one-year return exceeding 100%. With U.S. multi-state operators preparing to report Q2 2026 results over the next six weeks and the DEA’s administrative hearing calendar advancing on Schedule III rescheduling, institutional positioning ahead of catalyst-dense summer sessions may be firming the floor beneath sector valuations.
Market Analysis
MSOS closed Thursday’s abbreviated holiday-week session at $4.95, a gain of $0.12 or 2.48% on volume of 3.44 million shares — roughly 62% of the fund’s trailing 30-day average of 9.13 million. The below-average turnover reflects the shortened Independence Day holiday schedule rather than any erosion in institutional appetite; bid-ask depth at the close stood at 520,000 shares on the bid and 540,000 on the offer at a penny spread, signaling adequate liquidity for institutional-size executions.
The fund’s net asset value of $4.89 versus the $4.95 closing print represents a modest 1.2% premium to NAV — a common pattern for cannabis-sector ETFs during low-volume sessions when arbitrage mechanisms operate at reduced capacity. Traders tracking intraday dislocations typically exploit these premiums within the first 30 minutes of a full trading session.
On a performance basis, MSOS’s trailing 12-month return of 101.25% is the headline figure commanding attention from sector allocators. That compares to a YTD return of just 2.33%, illustrating a front-loaded recovery that ran hard through late 2025 before consolidating into a narrower 2026 trading band between $2.37 and $7.25. The fund currently trades in the middle of its 52-week range — neither stretched to the upside nor testing the prior lows that marked the sector’s trough.
The top constituent — Curaleaf Holdings (CURA) — represents 12.28% of total fund assets, consistent with MSOS’s structural overweight toward large-cap MSOs by revenue. Investors using MSOS as a proxy for the broader U.S. cannabis market should monitor Curaleaf’s Q2 2026 results closely, as performance skew from the top holding can materially influence the fund’s short-term price action.
For a real-time view of the underlying holdings and their individual price movements, see the cannabis stock tracker — updated throughout each trading session with price, volume, and 52-week range data.
Regulatory and Market Context
The Q2 2026 earnings season for U.S. cannabis operators is approximately two weeks from its first major reports. MSOs reporting in late July and August will provide the market with the first comprehensive look at how operators managed the persistent 280E federal tax burden in what may be one of the final quarters before rescheduling-linked relief becomes operative. The DEA’s administrative hearing calendar on Schedule III placement has advanced through the spring without material reversal — a development that has kept sector sentiment constructive even as individual stock prices remain compressed relative to pre-rescheduling-era highs.
State-level fundamentals continue to diverge. Illinois and New Jersey operators are reporting stable door counts but modest ASP compression as adult-use market maturations push pricing toward competitive equilibrium. Florida’s medical-to-recreational regulatory posture remains a wildcard, with legislative activity expected to resume in the fall session. Ohio’s adult-use rollout, now several months into its operational phase, is generating incremental volume data that will appear in Q2 disclosures from operators with meaningful Buckeye State exposure.
The broader macroeconomic context is mildly supportive. Consumer discretionary spend on cannabis has proven relatively inelastic through the current rate environment, and several operators have explicitly guided toward positive free cash flow generation in H2 2026 — a threshold that would mark a structural inflection point for a sector that consumed capital aggressively through its expansion phase.
Conclusion
MSOS’s 2.48% advance in a holiday-shortened week, stacked on top of a 101% trailing 12-month return, reflects a sector that has repriced substantially off its lows but has yet to fully reconstruct institutional confidence in durable earnings power. The next eight weeks of Q2 reporting will be the clearest read yet on whether U.S. cannabis operators are transitioning from restructuring stories to genuine earnings growth candidates. Investors monitoring the sector through MSOS should track both NAV alignment and constituent-level earnings surprises as the reporting window opens. The critical near-term catalyst remains the DEA hearing timeline — any adverse procedural development would likely compress the premium that the market has been quietly building into rescheduling-dependent MSO valuations.